Clin2
NCT07294144Possibly a fitRecruiting

Tofersen for ALS without SOD1 or FUS mutations

ALS (Amyotrophic Lateral Sclerosis)

Treatments studied

Tofersen

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests if tofersen, a drug that targets a protein linked to ALS, can help people who have ALS but do not have mutations in the SOD1 or FUS genes. It aims to slow disease progression in those diagnosed within the last 2 years.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older with a confirmed ALS diagnosis.
  • Your muscle weakness due to ALS must have started within the last 24 months.
  • You must have had genetic testing showing you do not have SOD1 or FUS mutations.
  • Your lung function (SVC) must be at least 50% of what is expected for someone your age, sex, and height.
  • You cannot have had prior treatment with certain other ALS drugs or gene therapies.
  • If you take riluzole or edaravone, you must be on a stable dose for a specific period before starting the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07077668Not yet recruiting· Early Phase 1
RAG-17 extended study for ALS with SOD1 mutation

This trial tests a new treatment called RAG-17 for people with ALS who have a specific genetic change (SOD1 mutation). The goal is to see if it can slow the disease.

NCT06649955Recruiting
Controlling nerve activity in ALS with brain stimulation

This study tests a non-invasive brain stimulation technique (called transcutaneous spinal direct current stimulation and transcranial magnetic stimulation) to see if it can calm overactive nerves in people with ALS. You may be a good fit if you have ALS that started less than 3 years ago and your breathing is still strong.

Boston, Massachusetts
NCT07259980Recruiting
Long-term safety of tofersen for SOD-1 ALS

This study checks the long-term safety of the drug tofersen (also known as Qalsody) for people with a specific genetic type of ALS caused by SOD1 mutations. It aims to make sure the drug is safe over time by watching participants from registry networks.

Boston, Massachusetts
NCT07287397Recruiting· Phase 1/Phase 2
Testing VTx-002 for safety in ALS patients

This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.

Phoenix, Arizona
NCT06556394Recruiting· Phase 1
Testing RAG-17 for ALS with SOD1 gene mutation

This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.

Beijing
NCT07080801Not yet recruiting· Early Phase 1
Testing RAG-21 for ALS with FUS gene mutations

This trial tests a new drug called RAG-21 for people with ALS who have a specific change in their FUS gene. The goal is to see if it is safe and if it can slow down the disease.

Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.